Hanmi Pharm, Samsung Securities to Host IR Event for 4 Biotechs

What the Hanmi Pharm–Samsung Securities Event Means for Investors

Hanmi Pharm and Samsung Securities will jointly host an event connecting biotech ventures with investors at Hanmi C&C Square in Songpa-gu, Seoul, on November 27, 2026. According to ChosunBiz, four companies will participate, with 50 people expected to attend. Investors should first distinguish between a meeting taking place and an investment being secured. The former is scheduled; the latter has yet to produce any results.

“Hanmi×Samsung Securities Bio Innovation Day” will give promising biotech ventures an opportunity to present their technologies and meet directly with investment professionals. The event’s stated scope extends to corporate presentations and one-on-one meetings. Because neither fundraising targets nor a list of participating investors has been disclosed, the event itself should not be interpreted as completed financing or a finalized business partnership.

Four Biotech Ventures and a Digital Convergence Medicine Platform

The four participating companies are Sleepforest, EasyCardio, Pi Healthcare, and Fraser Therapeutics. The theme is “The Future of Healthcare Opened by New Drugs and AI.” Hanmi Pharm will present its digital convergence medicine platform, while the participating companies will hold corporate presentations and one-on-one investor meetings.

The program’s investment significance lies in placing presentations and meetings within a single process. The platform presentation will outline the technological direction, the corporate presentations will allow each company to introduce its assets, and the one-on-one meetings will provide a point of contact for investment professionals to evaluate individual companies. This structure can initiate discussions around the technologies, but no investment criteria or contract terms have been disclosed.

Eligible attendees include venture capital firms, private equity funds, securities firms, and asset managers. Applications close on November 25, 2026, and the organizers will review submissions and notify applicants individually of their attendance status. The materials do not provide a detailed event schedule or participation fee.

Separating This Event from Hanmi Pharm’s Three Licensing Deals This Year

A Hanmi Pharm representative said the company completed three licensing deals this year, gaining experience in how innovative technologies earn market trust and lead to global partnerships. The representative also expressed hope that the event would connect biotech ventures’ technologies with investment and business partnerships while helping revitalize South Korea’s biotech and healthcare ecosystem. The first statement describes Hanmi Pharm’s achievements this year, while the second reflects expectations for the event. They should not be combined and treated as a single confirmed outcome.

Hanmi Pharm held its first such event with Kiwoom Securities in July. This event will be co-hosted with Samsung Securities. The only confirmed point is that the company is continuing to organize events connecting businesses with investors. No information has been provided on whether the previous event led to investment or business partnerships, so repeat events alone cannot establish that earlier outcomes are reproducible.

For this news to affect the earnings of related stocks, separate results must emerge after the event. If investment or business partnerships follow, the event’s economic significance will become more concrete. If it produces only corporate presentations and meetings, however, there will be no basis for estimating changes in Hanmi Pharm’s or Samsung Securities’ revenue or profit. That is why the outlook remains neutral at this stage.

Investment Checkpoints After the Event

• Form of outcome: Investors should monitor whether any investment or business partnership is announced after the November 27, 2026 event. This is the first test separating expectations for the event from tangible results.
• Participants: It has not yet been disclosed which investors from venture capital firms, private equity funds, securities firms, and asset managers will attend. A confirmed participant list would allow investors to assess the reach of these connections more precisely.
• Follow-up terms: No fundraising target has been provided, making it impossible to estimate the potential scale in advance. Any follow-up announcements should still be assessed by distinguishing among an announcement, a review, and a completed transaction.
• Company-level progress: The final indicator will be whether Sleepforest, EasyCardio, Pi Healthcare, and Fraser Therapeutics individually announce investment or partnership outcomes after the event.

The event’s value will depend more on subsequent outcomes than on attendance. If meetings convert into investment or business partnerships, the event’s role as a bridge will be validated. If no results are announced, investors should regard the participation of four companies and the 50-person gathering as a networking stage rather than an earnings catalyst.

This article was automatically summarized and analyzed from the original news report. View the original article (ChosunBiz)